The phase II trial (CAPRI trial) to use the ATR inhibitor ceralasertib (AZD6738) in combination with olaparib for recurrent ovarian cancer (NCT03462342) is ongoing [48], but has reported preliminary results of an overall response rate (ORR) of approximately 50% for the HRD patients with acquired PARPi resistance. This evidence concerns the gene ATR and ovarian cancer.